Astonea LabsShare price, financial results, shareholding and management

BSE SME · ASTONEALABPharma and cosmetics contract maker
astonea.org ↗Live price on BSE ↗ISIN INE0TG901011 · Lot 1,000 shares · ₹4.1 lakh
₹410.00
0.00% on the day
Close · 19 Nov 2026
Valuation
Market cap
₹431 cr
Stock P/E
95.6peers 21.3
Book value
₹55.2
Price to book
7.43
EV / operating profit
-
Market cap to sales
2.92
Returns and growth
ROCE · FY26
10.3%
ROE · FY26
11.7%
ROE, 3-year average
28.0%
Operating margin · FY26
9.1%peers 10.2%
Sales growth, 3 years
30.1%
Profit growth, 3 years
65.2%
Safety
Debt to equity
0.74peers 0.34
Borrowings
₹43 cr
Interest cover
2.7×
Cash from business / op. profit
-105%
Debtor days
129
Pledged
0.00%
Ownership and share
Promoter holding
72.30%
Change in promoter holding
0.00 pts
Shareholders
376
52-week high / low
₹420 / ₹118
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

Astonea Labs share price chart

₹410.00+188.53% 1 year

Close on 19 Nov 2026 · 0.00% on the day · Vol 7,000

Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 19 Nov 2026

1 month
+26.9%
3 months
+47.0%
6 months
+107.4%
1 year
+188.5%
Traded a day, 20 days
₹0.07 cr

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+51%-10%
3 years, a year+30%+65%
Latest half, H2 FY26+62%-4%

About Astonea Labs: business, products and customers

Astonea Labs makes medicines and beauty products such as tablets, capsules, creams and toothpaste for other brands at its plant in Haryana, and sells a few products under its own names. Its shares trade on BSE SME.

The company was set up in 2017 and runs one plant at Raipur Rani in Panchkula district, Haryana, with separate lines for medicines (tablets, hard and soft capsules, sachets, ointments) and for cosmetics (lotions, gels, creams, oils, soaps, toothpaste). Most of its work is contract manufacturing for pharmaceutical and cosmetic companies across India, some of whom export the goods through merchant exporters. It also sells its own Glow Up skin and hair care range, launched in 2022 and sold on Amazon and Tata 1MG, and Regero medicines, launched in 2024.

The business model shapes the numbers. In contract manufacturing the company buys the raw material and packing, makes the product and charges the customer per order, so revenue includes the full material cost and margins depend on how full the lines are and what each order pays. Customers have no long-term contracts, and stock and money owed by customers tie up working capital that has been funded by bank loans and loans from a director's relatives.

Read more about the business

What is new: the company listed on BSE SME in June 2025 and planned to spend issue money on an ointment line for exports, product registration in Bolivia, brand building and working capital. In late 2025 the board proposed changing how the issue money is used, a stake of a third in Damaira Pharmaceuticals and investments abroad. The offer document names no listed rivals; it says many small and large makers offer similar products and compete on quality, price and reliability.

From the offer document (RHP) and the annual report for FY25 with its AGM notice of December 2025.

Read the deeper study ↓

In its favour

  • Sales have grown fast: 30% a year over three years.
  • The promoters own a large part of the company: 72.30%.

To watch

  • Shareholder approval of the proposed changes to how the issue money is used (AGM notice, Annual Report 2025, p.68 and p.82).
  • Whether the ointment line for exports is bought and started (Offer document, p.95).
  • The proposed stake of a third in Damaira Pharmaceuticals (Annual Report 2025, p.67).
  • Loans from a director's relatives and the new board members appointed in November 2025 (Annual Report 2025, p.16 and p.19).
  • It paid no dividend in the past year.

From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.

Astonea Labs revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown fast. Last year profit fell even as sales rose, so the company kept less from each rupee of sales.

Sales and net profit, every year, ₹ crore
SalesNet profit
050100150Sales, FY22: 30 ₹ cr30Net profit, FY22: 0 ₹ cr0FY22Sales, FY23: 67 ₹ cr67Net profit, FY23: 1 ₹ cr1FY23Sales, FY24: 80 ₹ cr80Net profit, FY24: 4 ₹ cr4FY24Sales, FY25: 98 ₹ cr98Net profit, FY25: 5 ₹ cr5FY25Sales, FY26: 148 ₹ cr148Net profit, FY26: 4.5 ₹ cr4.5FY26
The latest halves, ₹ crore
SalesNet profit
0255075100Sales, H1FY25: 47 ₹ cr47Net profit, H1FY25: 2 ₹ cr2H1FY25Sales, H2FY25: 50.3 ₹ cr50.3Net profit, H2FY25: 3.2 ₹ cr3.2H2FY25Sales, H1FY26: 66.3 ₹ cr66.3Net profit, H1FY26: 1.4 ₹ cr1.4H1FY26Sales, H2FY26: 81.3 ₹ cr81.3Net profit, H2FY26: 3.1 ₹ cr3.1H2FY26

SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew more slowly than sales, so each rupee of sales left a little less profit.

Astonea Labs half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H1FY25H2FY25H1FY26H2FY26
Sales4750.2566.2981.29
Expenses4141.7160.9273.31
Operating profit78.545.377.99
OPM14.0%17.0%8.1%9.8%
Interest21.911.541.72
Depreciation22.462.152.84
Profit before tax34.281.773.85
Net profit23.221.423.10

Astonea Labs profit and loss

Full years to March, FY22 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY22FY23FY24FY25FY26
Sales30678098147.58
Expenses24606882134.23
Operating profit67121513.35
OPM19.0%11.0%15.0%16.0%9.1%
Other income00000.52
Interest22343.26
Depreciation44454.99
Exceptional and other items1··1·
Profit before tax11575.62
Tax rate100.0%0.0%20.0%28.6%19.8%
Net profit01454.51
EPS ₹0.621.685.366.934.49
Dividend payout0.0%0.0%0.0%0.0%0.0%

The years to FY25 come rounded to the nearest crore in the source.

Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.

A tax rate above 60% or below zero (FY22) comes from tax charged on a small or negative profit, as reported.

Astonea Labs profitability

Margins and returns on capital

Last year the company kept less from each rupee of sales than the year before. It earns a moderate return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%10%20%30%FY22: 19.0%19.0%FY22FY23: 11.0%11.0%FY23FY24: 15.0%15.0%FY24FY25: 16.0%16.0%FY25FY26: 9.1%9.1%FY26
Per cent
FY22FY23FY24FY25FY26
Operating margin19.0%11.0%15.0%16.0%9.1%
Tax rate100.0%0.0%20.0%28.6%19.8%
ROCE·7.4%16.3%17.5%10.3%
ROE·13.3%40.0%32.3%11.7%
Dividend payout0.0%0.0%0.0%0.0%0.0%

Astonea Labs debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown fast. Its loans are smaller than its own money. Last year the business used more cash than it brought in. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take about as long to pay as they did in FY24.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
0204060Net worth, FY22: 7 ₹ cr7Borrowings, FY22: 30 ₹ cr30FY22Net worth, FY23: 8 ₹ cr8Borrowings, FY23: 36 ₹ cr36FY23Net worth, FY24: 12 ₹ cr12Borrowings, FY24: 42 ₹ cr42FY24Net worth, FY25: 19 ₹ cr19Borrowings, FY25: 53 ₹ cr53FY25Net worth, FY26: 58 ₹ cr58Borrowings, FY26: 43 ₹ cr43FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-20-10010Cash from the business, FY22: -5 ₹ cr-5Net profit, FY22: 0 ₹ cr0FY22Cash from the business, FY23: -1 ₹ cr-1Net profit, FY23: 1 ₹ cr1FY23Cash from the business, FY24: 8 ₹ cr8Net profit, FY24: 4 ₹ cr4FY24Cash from the business, FY25: 9 ₹ cr9Net profit, FY25: 5 ₹ cr5FY25Cash from the business, FY26: -14 ₹ cr-14Net profit, FY26: 4.5 ₹ cr4.5FY26

Bars below the line are cash going out.

Astonea Labs balance sheet

At each 31 March · ₹ crore

₹ crore
FY22FY23FY24FY25FY26
Equity capital448811
Reserves3441147
Net worth78121958
Borrowings3036425343
Other liabilities1620273145
Total liabilities536481103146
Fixed assets2121222631
Capital work in progress00248
Investments00006
Other assets32435773101

Astonea Labs cash flow

₹ crore

₹ crore
FY22FY23FY24FY25FY26
Cash from operations-5-189-14
Cash from investing-3-3-8-11-20
Cash from financing840234
Net cash flow00000

Working capital

Days

Days
FY22FY23FY24FY25FY26
Debtor days235104116142129
Inventory days136121161161125
Days payable273128149144150
Cash conversion cycle9897128159103
Working capital days9833282274

Astonea Labs peers and competitors

Listed SME companies in the same industry

By sales, Astonea Labs is number 7 of the 34 listed SME companies in pharmaceuticals & biotechnology.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Infinium Pharmachem47138.719012.211.4%0.19
Zenith Drugs6817.21713.97.1%0.75
Mono Pharmacare1644.61660.42.4%1.79
Astonea Labs43195.61484.59.1%0.74
Influx Healthtech63230.814720.520.3%0.00
Jfl Life Sciences355.51316.48.9%0.47
Dipna Pharmachem113.512933.9%0.21
Trident Lifeline48125.31291922.0%0.73
Chandra Bhagat Pharma3210.511633.3%0.50
Quest Laboratories15410.31121516.3%0.08
KRM Ayurveda57328.61022030.0%0.00
Median of the 10 others11121.31309.310.2%0.34

Astonea Labs shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders has come down.

Promoters
72.30%
0.00 pts since Jun 25
Foreign investors (FIIs)
2.51%
at Sep 25; not in the latest pattern
Indian institutions (DIIs)
0.35%
at Sep 25; not in the latest pattern
Number of shareholders
376
1,014 in Jun 25

Astonea Labs shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Jun 25Sep 25Mar 26
Promoters72.30%72.30%72.30%
Foreign investors (FIIs)8.01%2.51%-
Indian institutions (DIIs)4.55%0.35%-
Number of shareholders1,014437376

Astonea Labs study: the business from its own documents

Read from 4 of the company's own documents

Astonea Labs key facts from the filings

Each figure with the document it comes from

Contract manufacturing
90.31%
Share of revenue from making products for other companies in April to December 2024; own brands gave 9.69%.Offer document, p.39
Exports
1.62%
Share of revenue from direct exports in April to December 2024; nearly all the rest was for Indian customers.Offer document, p.39
Top five customers
30.64%
Share of revenue in April to December 2024, down from 61.26% in FY23 as the customer base widened.Offer document, p.147
Tablet line use
77%
Tablet and hard capsule lines were 77% used at December 2024; soft capsules were at 30% and sachets at 5%.Offer document, p.150
Cosmetics line use
50% to 80%
Lotions, gels, creams and toothpaste ran at 50% to 80% at December 2024; oils were at 10%.Offer document, p.151
Show 5 more facts
FY25 revenue
₹97.5 cr
Revenue from operations in FY25, up from ₹80.2 cr in FY24.Annual Report 2025, p.14
FY25 profit
₹5.4 cr
Profit after tax in FY25, up from ₹4.1 cr in FY24.Annual Report 2025, p.14
Loans from relatives
₹5.5 cr
Unsecured loans from relatives of a director during FY25, beside ₹0.05 cr from Ashish Gulati.Annual Report 2025, p.19
Ointment line for exports
₹5.2 cr
Issue money set aside for new ointment machinery on the plant's second floor; the board later proposed changes to how issue money is used.Offer document, p.95; Annual Report 2025, p.68
Employees
217
People on the payroll at the time of the offer document, 67 of them in field sales.Offer document, p.152

What the company said, and what happened

The company's own statements, attributed, set against what it later reported; not newboard's estimates

The company has not given guidance on sales or profit. Its plan in the offer document was to spend issue money in FY25 and FY26 on an ointment line for exports, product registration in Bolivia, advertising and working capital. The AGM notice of December 2025 asks shareholders to approve changes to that use of money, a stake of a third in Damaira Pharmaceuticals and investments in companies abroad.

₹19.8 crIssue money for working capitalOffer document plan
₹5.2 crOintment line for exportsOffer document plan
33.33%Proposed stake in Damaira PharmaceuticalsAGM notice, Dec 2025

Is it a good business? Six questions

Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.

The company earns its money by making medicines and beauty products to order for other brands, using one plant that holds both drug and cosmetic approvals.

Its weak spots are thin margins on order-by-order work, a lot of money tied up in stock and money owed, and frequent changes in officers and in plans for the issue money.

WatchCan it set its own prices?No. Brand owners can move orders to many other contract makers, so prices are agreed order by order.
The evidence. The offer document says the contract manufacturing market is highly competitive, with many players chasing a limited pool of customers, which may lead to pricing pressure.Offer document, p.39
AverageHow strong is it against rivals?Making both medicines and cosmetics under one roof, with WHO-GMP and ISO approvals, is useful to customers, but many makers offer similar products.
The evidence. The offer document lists its certifications and says it faces competition from small and large domestic and international makers.Offer document, p.139 and p.151
AverageWho are its customers?Unnamed Indian pharma and cosmetic companies with no long-term contracts, though reliance on the biggest buyers has fallen.
The evidence. The top five customers fell from 61.26% of revenue in FY23 to 30.64% in April to December 2024; customers did not consent to being named.Offer document, p.147
WatchDoes it need a lot of money?Yes. Raw material, stock and money owed by customers need working capital, and the plant needs regular spending.
The evidence. The largest planned use of issue money was ₹19.8 cr for working capital, and cash from operations was negative in FY22 and FY23.Offer document, p.39 and p.95
AverageCan it keep finding new work?Several lines have room to make more, and a wider customer list helps, but there is no order book and exports are small.
The evidence. Soft capsules ran at 30% and sachets at 5% of capacity at December 2024; exports were 1.62% of revenue.Offer document, p.39 and p.150
AverageDo good and bad years swing a lot?Demand for medicines and personal care is steady, but margins have moved a lot with order mix and raw material prices.
The evidence. EBITDA margin was 18.80% in FY22, 10.52% in FY23 and 14.60% in FY24 on restated figures.Offer document, p.139

Who runs Astonea Labs?

Promoters, directors and officers; tap a name for the background

AGAshish GulatiPromoter and Managing Director

BSc in Motorsport Technology from Oxford Brookes University, United Kingdom (2013); earlier sales director at Shinto Organics for about a year (2016 to 2017). With the company since incorporation, leading quality, production, marketing and regulatory teams; Managing Director again from April 2022 for five years.

Offer document, p.171 and p.173
PSPooja SinghExecutive Director

Bachelor of Pharmacy from Dr. A.P.J. Abdul Kalam Technical University (2015) with over eight years in quality assurance, starting at Mediwell Healthcare; joined as Executive QA in August 2021 and a director since March 2024.

Offer document, p.172
VVikrantDirector, proposed as Executive Director

Appointed an additional non-executive director on 10 November 2025; the board proposed regularising the appointment and making it executive. The documents give no further background.

Annual Report 2025, p.16 and p.84
KVKaran Vir BindraIndependent Director

Law graduate from Panjab University (2012) and a fellow of the Institute of Company Secretaries of India, in practice at KV Bindra & Associates with over 10 years in governance and compliance.

Offer document, p.172
AAAkash AroraIndependent Director

B.Com from S.D. College, Muzaffarnagar and a chartered accountant (2013); earlier senior manager at HDFC Bank (2016 to 2019) and at Hero FinCorp.

Offer document, p.172

Astonea Labs latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H2 FY26: sales ₹81.3 cr (+62%), net profit ₹3.1 cr (-4%) on H2 FY25.
  • Shareholding, 31 March 2026: promoters unchanged at 72.30%.

Astonea Labs announcements

8 on record, latest first; each opens the filing on the exchange

Astonea Labs annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Offer document
Annual reports

Astonea Labs share split, bonus and dividends

From the corporate actions the company announces on the exchange

No share split, bonus issue or dividend is on record since listing.

Checks we ran on Astonea Labs' data · 8

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (1,05,11,000 shares).
  • ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • ✓The two half-years of FY26 add up to the full-year sales.
  • ✓Earnings per share moves in line with profit across the years shown.
  • ✓Revenue and profit are reported for every year shown, FY22 to FY26.
  • iPrices run to the close on 12 Oct 2026, from the exchange's daily figures.

Questions people ask about Astonea Labs

What does Astonea Labs do?

Astonea Labs makes medicines and beauty products such as tablets, capsules, creams and toothpaste for other brands at its plant in Haryana, and sells a few products under its own names. Its shares trade on BSE SME.

What is the share price of Astonea Labs?

₹410 at the close on 19 Nov 2026, from the exchange's daily figures.

What is the market cap of Astonea Labs?

₹431 cr at the close on 19 Nov 2026, on 1,05,11,000 shares.

What is the P/E of Astonea Labs?

95.6 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).

What are Astonea Labs' revenue and profit?

Revenue ₹148 cr and profit after tax ₹5 cr in FY26.

Who are the promoters of Astonea Labs?

Ashish Gulati; promoters held 72.30% at 31 March 2026.

What is Astonea Labs' website?

www.astonea.org

More SME companies like Astonea Labs

Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.

Every listed SME company in Pharmaceuticals & Biotechnology →

Built from 2 annual reports, 1 offer document, 1 result filing, 8 exchange announcements, 3 shareholding patterns and 5 years of reported results. Every figure carries its source; where the documents are silent, the page says so.